Department of Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ, 07103, USA.
World J Surg. 2010 Apr;34(4):658-68. doi: 10.1007/s00268-009-0296-8.
Tetralogy of Fallot (TOF) is a cyanotic congenital cardiac defect that was first described by Stenson in 1672 and later named for Fallot, who in 1888 described it as a single pathological process responsible for (1) pulmonary outflow tract obstruction, (2) ventricular septal defect (VSD), (3) overriding aortic root, and (4) right ventricular hypertrophy. The surgical history of TOF began with the development of the systemic to pulmonary artery shunt (BT shunt) by Blalock, Taussig, and Thomas in 1944. Ten years later complete repair of TOF was performed by Lillehei using cross-circulation and by Kirklin with a primitive cardiopulmonary bypass circuit. Notable contributions by several other surgeons including Bahnson, Ebert, Malm, Trusler, Barratt-Boyes, and Castaneda would lead us into the modern era of surgery. Today, complete repair of TOF is performed before six months of age with low mortality (<2%). In select cases a modified version of the BT shunt is still performed as the initial procedure. Long-term survival rates are excellent (85%-90%). Adult survivors with TOF are an ever-increasing population and may require reintervention, surgically or catheter based. Promising future innovations include percutaneous pulmonary valve replacement, tissue-engineered autologous valves and conduits, and genetic manipulation. This article presents a review of TOF, including the history of surgical treatment, present-day approaches, and long-term outcomes.
法洛四联症(TOF)是一种发绀性先天性心脏缺陷,于 1672 年由 Stenson 首次描述,后因 Fallot 于 1888 年将其描述为单一病理过程而得名,该过程可导致(1)肺流出道阻塞、(2)室间隔缺损(VSD)、(3)主动脉骑跨和(4)右心室肥厚。TOF 的手术历史始于 Blalock、Taussig 和 Thomas 于 1944 年开发的体肺动脉分流术(BT 分流术)。十年后,Lillehei 使用交叉循环,Kirklin 使用原始心肺旁路循环完成了 TOF 的完全修复。包括 Bahnson、Ebert、Malm、Trusler、Barratt-Boyes 和 Castaneda 在内的几位其他外科医生的杰出贡献将引领我们进入手术的现代时代。如今,TOF 在六个月大之前完成完全修复,死亡率较低(<2%)。在某些情况下,仍会进行 BT 分流术的改良版本作为初始手术。长期生存率非常高(85%-90%)。TOF 的成年幸存者人数不断增加,可能需要再次介入,包括手术或基于导管的介入。有前途的未来创新包括经皮肺动脉瓣置换术、组织工程自体瓣膜和导管以及基因操作。本文回顾了 TOF,包括手术治疗的历史、当前方法和长期结果。